Inhibition of TRPM7 blocks MRTF/SRF-dependent transcriptional and tumorigenic activity
Sandra Voringer1, Laura Schreyer1,2, Wiebke Nadolni1
1Walther-Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians-Universität München, Munich, Germany.
Abstract:
Myocardin-related transcription factors A and B (MRTFs) are coactivators of Serum Response Factor (SRF) that mediates the expression of genes involved in cell proliferation, migration and differentiation. There is mounting evidence that MRTFs and SRF represent promising targets for hepatocellular carcinoma (HCC) growth. Since MRTF-A nuclear localization is a prerequisite for its transcriptional activity and oncogenic properties, we searched for pharmacologically active compounds able to redistribute MRTF-A to the cytoplasm. We identified NS8593, a negative gating modulator of the transient receptor potential cation channel TRPM7, as a novel inhibitor of MRTF-A nuclear localization and transcriptional activity. Using a pharmacological approach and targeted genome editing, we investigated the functional contribution of TRPM7, a unique ion channel containing a serine-threonine kinase domain, to MRTF transcriptional and tumorigenic activity. We found that TRPM7 function regulates RhoA activity and subsequently actin polymerization, MRTF-A-Filamin A complex formation and MRTF-A/SRF target gene expression. Mechanistically, TRPM7 signaling relies on TRPM7 channel-mediated Mg2+ influx and phosphorylation of RhoA by TRPM7 kinase. Pharmacological blockade of TRPM7 results in oncogene-induced senescence of hepatocellular carcinoma (HCC) cells in vitro and in vivo in HCC xenografts. Hence, inhibition of the TRPM7/MRTF axis emerges as a promising strategy to curb HCC growth.
Insights
Researchers found that blocking the TRPM7 channel inhibits hepatocellular carcinoma (HCC) growth by preventing MRTF-A from entering the nucleus. This TRPM7/MRTF pathway offers a new therapeutic strategy for HCC.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Myocardin-related transcription factors (MRTFs) and Serum Response Factor (SRF) regulate genes crucial for cell functions.
- Aberrant MRTF/SRF activity is implicated in hepatocellular carcinoma (HCC) progression.
- MRTF-A nuclear localization is essential for its oncogenic role in HCC.
Purpose of the Study:
- To identify compounds inhibiting MRTF-A nuclear localization and transcriptional activity.
- To investigate the role of TRPM7 in MRTF-mediated gene expression and HCC tumorigenesis.
- To explore TRPM7 inhibition as a potential therapeutic strategy for HCC.
Main Methods:
- Drug screening to identify inhibitors of MRTF-A nuclear localization.
- Pharmacological inhibition and genome editing of TRPM7.
- Analysis of RhoA activity, actin polymerization, and MRTF-A/SRF target gene expression.
- In vitro and in vivo assessment of TRPM7 blockade effects on HCC cells and xenografts.
Main Results:
- NS8593, a TRPM7 inhibitor, was identified as an MRTF-A nuclear export modulator.
- TRPM7 regulates RhoA activity, actin polymerization, and MRTF-A/SRF transcriptional activity.
- TRPM7 signaling involves Mg2+ influx and RhoA phosphorylation by its intrinsic kinase domain.
- TRPM7 blockade induced oncogene-induced senescence in HCC cells and xenografts.
Conclusions:
- TRPM7 plays a critical role in regulating MRTF-A activity and HCC growth.
- TRPM7 inhibition effectively suppresses HCC progression both in vitro and in vivo.
- The TRPM7/MRTF axis represents a novel and promising therapeutic target for hepatocellular carcinoma.
More Related Videos
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MicroRNAs
MicroRNAs
PI3K/mTOR/AKT Signaling Pathway
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...


